INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO ANGIOID STREAKS

Angioid streaks result from rupture or dehiscence of a calcified and brittle Bruch's membrane between the retinal pigment epithelium and the choroid[2]. Angioid streaks (AS) were first described by Doyne in 1889 and in 1892 Knapp thought that they resembled vessels and used the term 'angioid streaks'[20]. Choroidal neovascularization (CNV) is the major cause of vision loss associated with angioid streaks with an estimated prevalence of between 72% and 86% (Bhatnagar et al. 2007)[18]. The natural history of CNV associated with AS has a poor prognosis, if left untreated.[3-4] We report a case of treatment of CNV in a patient with idiopathic angioid streaks with intravitreal bevacizumab [IVB](Avastin TM, Genentech, South San Francisco, CA, USA) (1.25 mg).